| 1.355 0.025 (1.88%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.76 | 1-year : | 1.91 |
| Resists | First : | 1.51 | Second : | 1.63 |
| Pivot price | 1.45 |
|||
| Supports | First : | 1.3 | Second : | 1.08 |
| MAs | MA(5) : | 1.36 |
MA(20) : | 1.46 |
| MA(100) : | 1.46 |
MA(250) : | 1.88 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 9.5  |
D(3) : | 5.8 |
| RSI | RSI(14): 40.6 |
|||
| 52-week | High : | 2.66 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MNOV ] has closed above bottom band by 16.5%. Bollinger Bands are 37.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.39 - 1.4 | 1.4 - 1.41 |
| Low: | 1.3 - 1.31 | 1.31 - 1.32 |
| Close: | 1.34 - 1.36 | 1.36 - 1.37 |
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Sun, 21 Apr 2024
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - Defense World
Fri, 19 Apr 2024
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely - Simply Wall St
Tue, 16 Apr 2024
MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 61% if they invested three years ago - Yahoo Movies Canada
Sat, 13 Apr 2024
MediciNova (NASDAQ:MNOV) Stock Price Passes Above 200-Day Moving Average of $1.62 - MarketBeat
Fri, 05 Apr 2024
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - Defense World
Fri, 29 Mar 2024
A History of Outperforming Analyst Forecasts and Beating the Odds: Medicinova Inc (MNOV) – Sete News - SETE News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 21.1 (%) |
| Shares Short | 334 (K) |
| Shares Short P.Month | 338 (K) |
| EPS | -0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.26 |
| Profit Margin | 0 % |
| Operating Margin | -990.1 % |
| Return on Assets (ttm) | -8.9 % |
| Return on Equity (ttm) | -13 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -7.98 |
| PEG Ratio | -0.4 |
| Price to Book value | 1.06 |
| Price to Sales | 66.46 |
| Price to Cash Flow | -8.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|